Immunovant reports Q3 net loss of $110.6M; cash $994.5M; D2T RA trial fully enrolled

Immunovant, Inc.

2026-Q3 EPS reported -$2.04

Net loss $110.6M ($0.61/sh) for Q3 FY26; non-GAAP net loss $97.5M.
Cash and equivalents $994.5M post-$550M financing; runway to GD commercial launch.
D2T RA potentially registrational trial fully enrolled; topline data H2 2026.
Batoclimab Phase 3 TED data expected H1 2026; IMVT-1402 GD and MG topline in 2027.
R&D expenses $98.9M, up from $94.5M YoY; driven by IMVT-1402 clinical activities.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.